ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.773,99
-0,70%
S&P 500
5.304,00
-0,06%
US Dollar vs BRL
5,1505
-0,04%
Bitcoin
67.850,09
-1,81%
Brent Oil
81,03
-0,61%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Qualigen Therapeutics Inc (QLGN)

  7. Qualigen Therapeutics Inc (QLGN) Notícias

QLGN

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:QLGN
DataHoraFonteTítuloCódigoCompanhia
14/05/202417:05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:QLGNQualigen Therapeutics Inc
03/05/202421:59Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
16/04/202408:00GlobeNewswire Inc.Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™NASDAQ:QLGNQualigen Therapeutics Inc
10/04/202409:00GlobeNewswire Inc.Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
09/04/202409:00GlobeNewswire Inc.Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
27/02/202409:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
14/11/202318:30GlobeNewswire Inc.Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023NASDAQ:QLGNQualigen Therapeutics Inc
07/11/202310:30GlobeNewswire Inc.Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
23/10/202309:30GlobeNewswire Inc.Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerNASDAQ:QLGNQualigen Therapeutics Inc
27/09/202309:30GlobeNewswire Inc.Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QLGNQualigen Therapeutics Inc
01/09/202317:15Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:QLGNQualigen Therapeutics Inc
17/08/202309:30GlobeNewswire Inc.Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
15/08/202309:30GlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023NASDAQ:QLGNQualigen Therapeutics Inc
14/08/202317:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QLGNQualigen Therapeutics Inc
01/08/202309:30GlobeNewswire Inc.Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
24/07/202309:15GlobeNewswire Inc.Qualigen Therapeutics Divests FastPack® Diagnostics BusinessNASDAQ:QLGNQualigen Therapeutics Inc
07/07/202318:08Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
26/06/202318:25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QLGNQualigen Therapeutics Inc
13/06/202318:16Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:QLGNQualigen Therapeutics Inc
05/06/202309:15GlobeNewswire Inc.Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
02/06/202317:11Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:QLGNQualigen Therapeutics Inc
16/05/202309:00GlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023NASDAQ:QLGNQualigen Therapeutics Inc
15/05/202318:14Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:QLGNQualigen Therapeutics Inc
02/05/202317:30GlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateNASDAQ:QLGNQualigen Therapeutics Inc
02/05/202309:15GlobeNewswire Inc.Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
21/04/202318:46GlobeNewswire Inc.Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingNASDAQ:QLGNQualigen Therapeutics Inc
18/04/202309:45GlobeNewswire Inc.Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FLNASDAQ:QLGNQualigen Therapeutics Inc
18/04/202308:30GlobeNewswire Inc.Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FLNASDAQ:QLGNQualigen Therapeutics Inc
31/03/202317:09Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:QLGNQualigen Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:QLGN

Seu Histórico Recente

USOTC
SKVI
Skinvisible (QB)
NASDAQ
CNOB
ConnectOne Bancorp
ASX
DLM
Dominion Minerals
USOTC
ABDXF
Abingdon Health (PK)
BIT
P1TTV7
NLBNPIT1TTV7 20241220 14
EU
VDPCD
Paris Domestic bond 0.75...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados